Phosphatidylserine Externalization in Cancer: Biology, Immune Suppression, and Emerging Theragnostic Strategies
Open Access
- 9 January 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 697
Abstract
Phosphatidylserine (PS) externalization is a conserved membrane stress signal that becomes chronically dysregulated in cancer cells and tumor-associated endothelium. In vivo, PS does not exist as a free lipid signal but is presented in specific membrane-associated forms, including apoptotic or stressed cell surfaces, PS-rich extracellular vesicles, and circulating lipid particles. Unlike apoptosis-associated transient PS exposure, malignant PS externalization arises from metabolic rewiring, oxidative stress, epigenetic silencing of flippases, and microenvironmental cues, creating an immunosuppressive interface across the tumor–host boundary. This review synthesizes mechanistic, immunological, and clinical evidence on PS biology, including its roles in tumor immune evasion, extracellular vesicle-mediated systemic suppression, and vascular remodeling. We further summarize the development and evaluation of PS-targeted therapeutic platforms—such as bavituximab, SapC-DOPS/BXQ-350, and PS-directed imaging agents—and highlight their translational potential in combination with radiotherapy, chemotherapy, and checkpoint inhibitors. Chronic PS externalization, as manifested through distinct cellular and vesicular carriers, represents a unifying biomarker of tumor stress, immune suppression, and therapeutic vulnerability, offering a next-generation axis for theragnostic cancer management.Keywords
Funding Information
- Ministry of Health & Welfare, Republic of Korea (RS-2025-02243055)
This publication has 57 references indexed in Scilit:
- The cancer-immunity cycle: Indication, genotype, and immunotypeImmunity, 2023
- Phosphatidylserine targeting peptide-functionalized pH sensitive mixed micelles for enhanced anti-tumor drug deliveryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2020
- Tumor-derived exosomes, microRNAs, and cancer immune suppressionSeminars in Immunopathology, 2018
- Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung CancerClinical Lung Cancer, 2016
- 99mTc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trialsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in miceJournal of Controlled Release, 2014
- The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cellsEuropean Journal of Immunology, 2013
- TMEM16F Forms a Ca2+-Activated Cation Channel Required for Lipid Scrambling in Platelets during Blood CoagulationCell, 2012
- Lipid flippases and their biological functionsCellular and Molecular Life Sciences, 2006
- Structural changes in a binary mixed phospholipid bilayer of DOPG and DOPS upon saposin C interaction at acidic pH utilizing 31P and 2H solid-state NMR spectroscopyBiochimica et Biophysica Acta (BBA) - Biomembranes, 2005